VX-A902

VX-A902 is a preclinical antibody-drug conjugate (ADC) being developed by VERAXA Biotech for the treatment of HER2-positive breast cancer. Utilizing VERAXA's proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, the drug consists of a HER2-targeting monoclonal antibody site-specifically conjugated to a potent cytotoxic payload. This design aims to enhance the therapeutic index by ensuring stable delivery of the toxin to tumor cells while minimizing systemic toxicity. VERAXA Biotech, a Heidelberg-based company, is advancing VX-A902 as part of its next-generation ADC pipeline, leveraging advanced click-chemistry for precise payload attachment.